Xenon Pharmaceuticals Shares Drop On Proposed Public Offering
Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted…
Recap of Tuesday’s Biotech Catalysts – End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Ionis shares are trading low 4 percent at $35.10 in the after-hours session
Looking Into Xenon Pharmaceuticals’s Return On Capital Employed
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67 million.
Recap: Xenon Pharmaceuticals Q1 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Xenon Pharmaceuticals Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $8.77M Beat $8.70M Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14.63 percent. This is a 16.67 percent increase over losses of $(0.42) per share
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Xenon Pharmaceuticals’s Return On Capital Employed Overview
Xenon Pharmaceuticals (NASDAQ:XENE) brought in sales totaling $3.74 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.52%, resulting in a loss of $25.56 million.
Recap: Xenon Pharmaceuticals Q4 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
